2篇
您的检索式：作者名="Dengxiang Liu"
|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Noncontrast-enhanced MRI-based Noninvasive Score for Portal Hypertension(CHESS1802):An International Multicenter Study显示文摘Background and Aims:This study aimed to determine the performance of the non-invasive score using noncontrastenhanced MRI(CHESS-DIS score)for detecting portal hy-pertension in cirrhosis.Methods:In this international multicenter,diagnostic study(ClinicalTrials.gov,NCT03766880),patients with cirrhosis who had hepatic venous pressure gradient(HVPG)measurement and noncontrast-enhanced MRI were prospectively recruited from four university hospitals in China(n=4)and Turkey(n=1)between December 2018 and April 2019.A cohort of patients was retrospectively recruited from a university hospital in Italy between March 2015 and November 2017.After segmentation of the liver on fat-suppressed T1-weighted MRI maps,CHESS-DIS score was calculated automatically by an in-house developed code based on the quantification of liver surface nodularity.Results:A total of 149 patients were included,of which 124 were from four Chinese hospitals(training cohort)and 25 were from two international hospitals(validation cohort).A positive correlation between CHESS-DIS score and HVPG was found with the correlation coefficients of 0.36(p<0.0001)and 0.55(p<0.01)for the training and validation cohorts,respectively.The area under the receiver operating characteristic curve of CHESS-DIS score in detection of clinically significant portal hypertension(CSPH)was 0.81 and 0.9 in the training and validation cohorts,respectively.The intra-class correlation coefficients for assessing the inter-and intra-observer agreement were 0.846 and 0.841,respectively.Conclusions:A non-invasive score using noncontrast-enhanced MRI was developed and proved to be significantly correlated with invasive HVPG.Besides,this score could be used to detect CSPH in patients with cirrhosis. | Yanna Liu Tianyu Tang NecatiÖrmeci Yifei Huang Jitao Wang Xiaoguo Li Zhiwei Li Weimin An Dengxiang Liu Chunqing Zhang Changchun Liu Jinqiang Liu Chuan Liu Guangchuan Wang Cristina Mosconi Alberta Cappelli Antonio Bruno Seray Akçalar EmrecanÇelebioğlu EvrenÜstüner Sadık Bilgiç Zeynep Ellik ÖzgünÖmer Asiller Lei Li Haijun Zhang Ning Kang Dan Xu Ruiling He Yan Wang Yang Bu Ye Gu Shenghong Ju Rita Golfieri Xiaolong Qi | 2021 | Journal of Clinical and Translational Hepatology2021，9，6： | 3 |
| 2 | Immunogenicity and safety of a booster COVID-19 vaccination in patients with chronic liver disease:A multicenter study显示文摘Aim:Patients with chronic liver disease(CLD),especially cirrhosis,are at a high risk of severe illness or death from coronavirus disease-2019(COVID-19)and may have a suboptimal immune response to the severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)vaccine.This study aimed to evaluate the safety and immunogenicity of the COVID-19 booster vaccination in patients with CLD.Methods:The study protocol was prospectively registered at ClinicalTrials.gov(No.NCT05204602)after approval by the Ethics Committee.Adult participants with CLD were enrolled in this multicenter prospective study.They completed two doses of the inactivated COVID-19 vaccine and received booster doses at least 6 months later.Adverse reactions were recorded within 14 days after the booster dose.Serum samples of the enrolled patients were collected before and after booster vaccination and tested for SARS-CoV-2 receptor-binding domain(RBD)immunoglobulin G and neutralizing anti-bodies.The chi-squared or Fisher's exact test was used to compare categorical data,and the Mann-Whitney U test was used to compare continuous variables.Two-sided p<0.05 were considered statistically significant.Results:In total,63 patients were enrolled from four hospitals in China,including 29 patients with cirrhosis.The median age of all patients was 55 years,and 61.9%(39/63)were male.The vaccines were well tolerated;most adverse reactions were mild and transient,and injection site pain(6.4%;4/63)and fatigue(3.2%,2/63)were the most frequent local and systemic adverse events.Following the booster vaccination,our results showed that in the whole cohort,the levels and positive rates of anti-RBD IgG and neutralizing antibodies were significantly higher than baseline levels(all p<0.05).Conclusions:The inactivated COVID-19 booster vaccine was safe and significantly increased antibody levels and positivity rates following standard vaccination regimens in patients with CLD,especially those with cirrhosis. | Jitao Wang Jingwen Ai Huiling Xiang Yanliang Zhang Zhiyun Hou Qiran Zhang Jiaojian Lv Shubo Chen Chuan Liu Qianqian Li Jing Liang Faren Xie Shujun Jiang Nina Zhang Aiguo Zhang Xiaolin Lan Xuying Zhang Jinlong Li Dengxiang Liu Wenchuan Wang Wei Rao Zhang Qun Qiuju Tian Xiaolong Qi Wenhong Zhang | 2023 | Portal Hypertension & Cirrhosis2023，2，3： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员